CO6160307A2 - Compuestos de pirazolina y su uso y composiciones farmaceuticas - Google Patents
Compuestos de pirazolina y su uso y composiciones farmaceuticasInfo
- Publication number
- CO6160307A2 CO6160307A2 CO09040130A CO09040130A CO6160307A2 CO 6160307 A2 CO6160307 A2 CO 6160307A2 CO 09040130 A CO09040130 A CO 09040130A CO 09040130 A CO09040130 A CO 09040130A CO 6160307 A2 CO6160307 A2 CO 6160307A2
- Authority
- CO
- Colombia
- Prior art keywords
- group
- alkyl
- hydrogen
- substituents
- heterocyclyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
1.- Un compuesto, o una sal farmacéuticamente aceptable del compuesto, en el que el compuesto tiene la estructura de Fórmula I:en la que;X se selecciona entre el grupo constituido por -CH2- y -O-; R1 se selecciona entre el grupo constituido por alquilo, cicloalquilo, cicloalquenilo, fenilo, y heterociclilo, donde el sustituyente heterociclilo es un anillo heterociclilo de cinco o seis miembros que comprende al menos un heteroátomo en el anillo seleccionado entre oxígeno, azufre y nitrógeno; y donde los sustituyentes alquilo, cicloalquilo, cicloalquenilo, fenilo y heterociclilo pueden estar opcionalmente sustituidos con uno o más sustituyentes seleccionados independientemente entre el grupo constituido por hidroxi, halógeno, alquilo y haloalquilo; R2 se selecciona entre el grupo constituido por hidrógeno y alquilo;R3A y R3B se seleccionan independientemente entre el grupo constituido por hidrógeno y alquilo; R4, R6 y R7 se seleccionan independientemente entre el grupo constituido por hidrógeno, halógeno, hidroxi, alquilo, haloalquilo, hidroxialquilo y alcoxi; R5 se selecciona entre el grupo constituido por hidrógeno, -(CH2)mOR50, -(CH2)mC(O)R50, -(CH2)mC(O)OR50, -(CH2)mC(O)NR51R52, -(CH2)mNR51R52, -(CH2)mN(R51)C(O)R52 y -(CH2)mS(O)nR50;m es 0, 1, 2, 3, 4, 5 ó 6, n es o,1 ó 2; R50 se selecciona entre el grupo constituido por hidrógeno y alquilo; R51 y R52 se seleccionan independientemente entre el grupo constituido por hidrógeno y alquilo; o R51 y R52 junto con el nitrógeno al que están unidos forman un anillo heterociclilo de cinco o seis miembros; donde los sustituyentes alquilo R50, R51 y R52 y el sustituyente heterociclilo R51/R52 pueden estar independiente y opcionalmente sustituidos con uno o más sustituyentes seleccionados entre el grupo constituido por halógeno, pirolidinilo, -OR53, -C(O)R53, -C(O)OR53, -C(O)NR54R55, -NR54R55, -N(R56)C(O)R53; -S(O)pR53 y -S(O)pNR54R55, p es o,1 ó 2; ...
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86360606P | 2006-10-31 | 2006-10-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6160307A2 true CO6160307A2 (es) | 2010-05-20 |
Family
ID=39027523
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO09040130A CO6160307A2 (es) | 2006-10-31 | 2009-04-21 | Compuestos de pirazolina y su uso y composiciones farmaceuticas |
Country Status (40)
Country | Link |
---|---|
US (3) | US7781428B2 (es) |
EP (1) | EP2089367B1 (es) |
JP (1) | JP4977760B2 (es) |
KR (1) | KR101107800B1 (es) |
CN (1) | CN101541757A (es) |
AP (1) | AP2527A (es) |
AR (1) | AR063529A1 (es) |
AT (1) | ATE537151T1 (es) |
AU (1) | AU2007315884B2 (es) |
BR (1) | BRPI0717937A2 (es) |
CA (1) | CA2667966C (es) |
CL (1) | CL2007003154A1 (es) |
CO (1) | CO6160307A2 (es) |
CR (1) | CR10725A (es) |
CU (1) | CU23779B7 (es) |
CY (1) | CY1112311T1 (es) |
DK (1) | DK2089367T3 (es) |
EA (1) | EA016370B1 (es) |
ES (1) | ES2375877T3 (es) |
GE (1) | GEP20115239B (es) |
GT (1) | GT200700096A (es) |
HN (1) | HN2007000437A (es) |
HR (1) | HRP20120078T1 (es) |
IL (1) | IL198241A0 (es) |
MA (1) | MA30821B1 (es) |
MX (1) | MX2009004662A (es) |
MY (1) | MY145795A (es) |
NI (1) | NI200900071A (es) |
NO (1) | NO20091741L (es) |
NZ (1) | NZ575923A (es) |
PE (1) | PE20081472A1 (es) |
PL (1) | PL2089367T3 (es) |
PT (1) | PT2089367E (es) |
RS (2) | RS20090208A (es) |
SI (1) | SI2089367T1 (es) |
TN (1) | TN2009000160A1 (es) |
TW (1) | TWI357327B (es) |
UA (1) | UA92670C2 (es) |
UY (1) | UY30670A1 (es) |
WO (1) | WO2008053300A1 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI431010B (zh) | 2007-12-19 | 2014-03-21 | Lilly Co Eli | 礦皮質素受體拮抗劑及使用方法 |
EP2592071B1 (en) * | 2009-10-29 | 2019-09-18 | Bristol-Myers Squibb Company | Tricyclic heterocyclic compounds |
EP3238781B1 (en) | 2010-05-10 | 2019-07-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for the treatment of fluid accumulation in and/ or under the retina |
CA2798831A1 (en) | 2010-05-11 | 2011-11-17 | Pfizer Inc. | Morpholine compounds as mineralocorticoid receptor antagonists |
JP6180930B2 (ja) | 2010-06-16 | 2017-08-16 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 創傷治癒過程における再上皮化を刺激するための方法及び組成物 |
CN102372710A (zh) * | 2010-08-18 | 2012-03-14 | 山东轩竹医药科技有限公司 | 作为盐皮质激素受体拮抗剂的并环类化合物 |
US10172907B2 (en) | 2010-10-05 | 2019-01-08 | Nova Southeastern University | Compositions comprising β-arrestin 1 and methods of use thereof for therapeutic modulation of aldosterone levels in heart disease |
EA029518B1 (ru) | 2014-06-30 | 2018-04-30 | Астразенека Аб | Бензоксазиноновые амиды в качестве модуляторов минералокортикоидного рецептора |
US20180280414A1 (en) | 2015-10-13 | 2018-10-04 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation |
ES2973248T3 (es) | 2016-07-26 | 2024-06-19 | Inst Nat Sante Rech Med | Antagonista del receptor mineralocorticoide para el tratamiento de la osteoartritis |
US10633354B2 (en) | 2016-09-02 | 2020-04-28 | Bristol-Myers Squibb Company | Substituted tricyclic heterocyclic compounds |
WO2019032632A1 (en) | 2017-08-09 | 2019-02-14 | Bristol-Myers Squibb Company | ALKYLPHENYL COMPOUNDS |
US11059784B2 (en) | 2017-08-09 | 2021-07-13 | Bristol-Myers Squibb Company | Oxime ether compounds |
CN109051490A (zh) | 2018-09-18 | 2018-12-21 | 深圳市鲸仓科技有限公司 | 可移动式密集存拣装置 |
JP2023518168A (ja) | 2020-03-11 | 2023-04-28 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 対象が中心性漿液性脈絡網膜症を有するか、または有する危険性があるかどうかを決定する方法。 |
WO2023031277A1 (en) | 2021-08-31 | 2023-03-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of ocular rosacea |
CN113679716B (zh) | 2021-10-13 | 2024-03-26 | 史大永 | 溴酚-吡唑啉化合物在治疗猫冠状病毒疾病中的应用 |
CN114230457B (zh) * | 2022-01-04 | 2023-06-09 | 中山大学 | 一类2-亚苄基四氢萘酮衍生物及其制备方法和应用 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1086068A (en) | 1964-09-02 | 1967-10-04 | Ici Ltd | Process for the whitening of polymeric materials and nitrogen-containing polycyclic compounds for use therein |
BE789948A (fr) | 1971-10-13 | 1973-04-11 | Sandoz Sa | Nouveaux derives du pyrazole, leur preparation et leur application comme medicaments |
US3816438A (en) | 1972-12-22 | 1974-06-11 | Sandoz Ag | 2h(1)-benzothiepino(5,4-c)-pyrazoles and(1)-benzothiopyrano(4,3-c)-pyrazoles |
US3843666A (en) | 1973-05-29 | 1974-10-22 | Sandoz Ag | Process for preparing substituted indeno,naphtho and cyclohepta pyrazoles |
US4866025A (en) | 1988-09-30 | 1989-09-12 | Eastman Kodak Company | Thermally-transferable fluorescent diphenylpyrazolines |
DK0623122T3 (da) | 1992-01-23 | 1997-04-21 | Pfizer | Benzopyran og beslægtede LTB4-antagonister |
GB9318691D0 (en) | 1993-09-09 | 1993-10-27 | Merck Sharp & Dohme | Therapeutic agents |
AR006520A1 (es) | 1996-03-20 | 1999-09-08 | Astra Pharma Prod | Derivados de 2-arilpirazolisoquinolina y cinolinona y procedimiento para su preparacion. |
WO1998009969A1 (en) * | 1996-09-05 | 1998-03-12 | Astra Pharmaceuticals Ltd. | Novel aryl-pyridazines |
JPH10273467A (ja) | 1997-01-29 | 1998-10-13 | Snow Brand Milk Prod Co Ltd | 新規テトラロン又はベンゾピラノン誘導体及びその製造方法 |
IT1292092B1 (it) | 1997-06-05 | 1999-01-25 | Geange Ltd | Impiego di derivati eterociclici aromatici azotati nel trattamento topico di affezioni di tessuti epiteliali |
DE69918542T2 (de) | 1998-04-30 | 2005-08-18 | Abbott Gmbh & Co. Kg | Substituierte trizyklische pyrazolderivate mit protein kinase aktivität |
US6432974B1 (en) | 2000-02-04 | 2002-08-13 | Wyeth | Pyrrolo-isoquinoline and tetra-hydropyrrolo-isoquinoline derivatives and their use as mediators of the 5-HT7 receptor |
JP4399269B2 (ja) | 2002-03-08 | 2010-01-13 | メルク エンド カムパニー インコーポレーテッド | 有糸分裂性キネシン阻害薬 |
US7250442B2 (en) | 2002-03-15 | 2007-07-31 | Eli Lilly And Company | Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators |
TW200400816A (en) | 2002-06-26 | 2004-01-16 | Lilly Co Eli | Tricyclic steroid hormone nuclear receptor modulators |
MXPA05001367A (es) | 2002-08-02 | 2005-04-28 | Vertex Pharma | Composiciones de pirazol utiles como inhibidores de gsk-3. |
CN1681501A (zh) | 2002-09-18 | 2005-10-12 | 辉瑞产品公司 | 作为转化生长因子(tgf)抑制剂的吡唑衍生物 |
CN1742007A (zh) | 2003-01-22 | 2006-03-01 | 伊莱利利公司 | 甾族激素核受体的吲哚衍生物调控剂 |
SI1697350T1 (sl) * | 2003-12-19 | 2008-12-31 | Lilly Co Eli | Modulatorji jedrnega receptorja tricikličnih steroidnih hormonov |
JP2007230869A (ja) | 2004-04-05 | 2007-09-13 | Takeda Chem Ind Ltd | アルドステロン受容体拮抗剤 |
WO2006010142A2 (en) | 2004-07-14 | 2006-01-26 | Ligand Pharmaceuticals, Inc. | Mineralocorticoid receptor modulator compounds, processes for their preparation, and their use |
BRPI0513677B8 (pt) | 2004-07-30 | 2021-05-25 | Exelixis Inc | derivados de pirrol como agentes farmacêuticos |
US20110144128A1 (en) | 2005-01-10 | 2011-06-16 | Exelixis, Inc. | Heterocyclic Carboxamide Compounds as Steroid Nuclear Receptors Ligands |
WO2006077821A1 (ja) | 2005-01-19 | 2006-07-27 | Dainippon Sumitomo Pharma Co., Ltd. | アルドステロン受容体調節剤としての芳香族スルホン化合物 |
AU2006212863A1 (en) | 2005-02-10 | 2006-08-17 | Merck Sharp & Dohme Corp. | Mitotic kinesin inhibitors |
-
2007
- 2007-10-17 RS RSP-2009/0208A patent/RS20090208A/sr unknown
- 2007-10-17 KR KR1020097008836A patent/KR101107800B1/ko not_active IP Right Cessation
- 2007-10-17 SI SI200730830T patent/SI2089367T1/sl unknown
- 2007-10-17 GE GEAP200711240A patent/GEP20115239B/en unknown
- 2007-10-17 NZ NZ575923A patent/NZ575923A/en not_active IP Right Cessation
- 2007-10-17 PT PT07825488T patent/PT2089367E/pt unknown
- 2007-10-17 BR BRPI0717937-5A2A patent/BRPI0717937A2/pt not_active IP Right Cessation
- 2007-10-17 ES ES07825488T patent/ES2375877T3/es active Active
- 2007-10-17 RS RS20120051A patent/RS52203B/en unknown
- 2007-10-17 AT AT07825488T patent/ATE537151T1/de active
- 2007-10-17 DK DK07825488.5T patent/DK2089367T3/da active
- 2007-10-17 UA UAA200903302A patent/UA92670C2/ru unknown
- 2007-10-17 EA EA200970341A patent/EA016370B1/ru not_active IP Right Cessation
- 2007-10-17 PL PL07825488T patent/PL2089367T3/pl unknown
- 2007-10-17 CN CNA2007800433330A patent/CN101541757A/zh active Pending
- 2007-10-17 AU AU2007315884A patent/AU2007315884B2/en not_active Ceased
- 2007-10-17 CA CA2667966A patent/CA2667966C/en not_active Expired - Fee Related
- 2007-10-17 WO PCT/IB2007/003207 patent/WO2008053300A1/en active Application Filing
- 2007-10-17 EP EP07825488A patent/EP2089367B1/en active Active
- 2007-10-17 AP AP2009004822A patent/AP2527A/xx active
- 2007-10-17 MX MX2009004662A patent/MX2009004662A/es active IP Right Grant
- 2007-10-17 JP JP2009533977A patent/JP4977760B2/ja not_active Expired - Fee Related
- 2007-10-17 MY MYPI20091613A patent/MY145795A/en unknown
- 2007-10-24 US US11/923,248 patent/US7781428B2/en not_active Expired - Fee Related
- 2007-10-29 UY UY30670A patent/UY30670A1/es not_active Application Discontinuation
- 2007-10-29 AR ARP070104787A patent/AR063529A1/es not_active Application Discontinuation
- 2007-10-30 PE PE2007001482A patent/PE20081472A1/es not_active Application Discontinuation
- 2007-10-30 GT GT200700096A patent/GT200700096A/es unknown
- 2007-10-30 TW TW096140838A patent/TWI357327B/zh not_active IP Right Cessation
- 2007-10-31 CL CL200703154A patent/CL2007003154A1/es unknown
- 2007-10-31 HN HN2007000437A patent/HN2007000437A/es unknown
-
2009
- 2009-04-17 CR CR10725A patent/CR10725A/es not_active Application Discontinuation
- 2009-04-17 CU CU20090058A patent/CU23779B7/es not_active IP Right Cessation
- 2009-04-20 IL IL198241A patent/IL198241A0/en unknown
- 2009-04-21 CO CO09040130A patent/CO6160307A2/es unknown
- 2009-04-24 TN TNP2009000160A patent/TN2009000160A1/fr unknown
- 2009-04-29 NI NI200900071A patent/NI200900071A/es unknown
- 2009-04-30 MA MA31831A patent/MA30821B1/fr unknown
- 2009-05-04 NO NO20091741A patent/NO20091741L/no not_active Application Discontinuation
-
2010
- 2010-07-12 US US12/834,117 patent/US20100280016A1/en not_active Abandoned
-
2011
- 2011-10-20 US US13/277,270 patent/US20120035131A1/en not_active Abandoned
-
2012
- 2012-01-23 HR HR20120078T patent/HRP20120078T1/hr unknown
- 2012-01-23 CY CY20121100076T patent/CY1112311T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6160307A2 (es) | Compuestos de pirazolina y su uso y composiciones farmaceuticas | |
AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
PE20210040A1 (es) | Moduladores de la via de estres integrada | |
RS52562B (en) | (3-ARIL-PIPERAZINE-1-IL) DERIVATI 6,7-DIALCOKSIQUINZOLINE, 6,7-DIALCOKSIFTALAZINE I | |
PE20130155A1 (es) | Derivados de ariletinilo | |
ECSP099638A (es) | Nuevo compuesto de adenina | |
AR063015A1 (es) | Derivados de quinazolinona 5-sustituida y composiciones que los comprenden y metodos para utilizarlos en el tratamiento del cancer | |
AR055592A1 (es) | Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace) | |
CO6190521A2 (es) | Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta -9 desaturasa | |
AR076900A1 (es) | Derivados heterociclicos nitrogenados utiles como agentes antivirales, composiciones farmaceuticas que los contienen y uso de los mismos como inhibidores del vhc | |
AR084277A1 (es) | Compuestos utiles para el tratamiento del sida | |
AR067757A1 (es) | Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales. | |
AR088535A1 (es) | Derivados de amidas de aminoacidos sustituidos con n-urea como moduladores de receptor formil peptido del receptor del tipo 1 (fprl-1) | |
UY29346A1 (es) | 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2 | |
AR054081A1 (es) | Derivados de pirimidina, procesos de obtencion y composiciones farmaceuticas | |
AR082696A1 (es) | Derivados heterociclicos nitrogenados de 1,2,4-oxadiazol, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades cardiovasculares e inflamatorias, entre otras | |
NO20075768L (no) | Hydroksybenzamidderivater og deres anvendelse som inhibitorer av HSP90 | |
CO6160232A2 (es) | Derivados de bencimidazol | |
AR042691A1 (es) | Agonistas inversos del receptor cb1 procedimientos de obtencion y composiciones farmaceuticas. | |
ECSP088965A (es) | Derivados de 2-tioxantina que actúan como inhibidores de la mpo | |
CO6241121A2 (es) | Derivados de azapeptidps | |
AR075583A1 (es) | Derivados de isoxazol/o-piridina con eslabon etilo o etenilo | |
CO6150150A2 (es) | Derivados de 7-alquinil-1,8-naftiridonas su prepacion y su aplicacion en terapeutica | |
AR094762A1 (es) | Compuestos de hexahidropirano[3,4-d][1,3]tiazin-2-amina sustituida con heteroarilo | |
CO2020001326A2 (es) | Nuevos compuestos heterocíclicos como inhibidores de cdk8/19 |